EU first approved NOAC Xarelto
EU approved the very first NOAC (or novel oral anticoagulant) Xarelto (rivaroxaban) for broad application. With Bayer and Janssen at the helm, Xarelto can now be broadly used for patients suffering from atrial fibrillation (AF)….